Is the price of moboxetinib reimbursed by medical insurance? How much does the patient pay out of pocket?

Mobocertinib/Mobocertinib （Mobocertinib) The original drug has been approved by the State Food and Drug Administration for marketing in China. However, due to its short time on the market, it has not been included in medical insurance. Patients need to pay for the purchase in full. Mobosetinib, as a new type of EGFR TKI drug, has shown excellent efficacy in the treatment of patients with EGFR gene mutation-positive non-small cell lung cancer.

By inhibitingEGFR mutations and T790M mutations, Mobosetinib significantly extended survival, improved disease control rate, and effectively managed drug resistance while maintaining relatively good safety and tolerability. In clinical studies, 32 of 114 patients with non-small cell lung cancer (28%) had a partial response to moboxetinib treatment. In these patients, response to treatment lasted approximately 17.5 months. Nearly 59% of patients who responded had their responses sustained for at least 6 months. Median overall survival was 24 months (2 years). This drug provides patients with new treatment hope, improves their quality of life, and brings important medical progress to patients with advanced non-small cell lung cancer.

Mobosetinib original drug sold in China, the common specification40mg*112 pills per box, is very expensive.The Hong Kong version of the original drug specification40mg*30 pills per box is priced at more than 7,000 RMB (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory40mg*120 pills per boxThe pricemay be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.